Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 2014 The Biomass Power ... five years to 2014. The industry's expansion has been ... credits that encouraged the use of biomass power. Furthermore, ... (RPSs), which require local utilities to generate electricity from ... portfolio. Increased campaigning for green technology also influenced industry ...
(Date:10/18/2014)... 18, 2014 The “Global Diagnostic ... Monitor), by End-user (Hospitals, Home/Ambulatory, Research Center, Physician ... 12) -Global Forecast to 2020” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/17/2014)... Germany , October 17, 2014 ... Translational research in cancer and other diseases will ... American Society of Human Genetics annual meeting   ... to Ingenuity ®  Knowledge Base greatly exceeds any ... Ingenuity ®  Variant Analysis™ adds fully integrated ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The ... Critical Radiant Boilers, Super Critical Boilers, Ultra Super ... (Combined Cycle Plants, Cogeneration Plants, Natural Gas Power ... Geography - Global Trends & Forecasts to 2019", ... with the analysis and forecast of the global ...
Breaking Biology Technology:Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 3QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 4QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 6Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 2Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 3Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 4Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 5
... study of Global Methylation with results in half the time ... ... ST. LOUIS, Oct. 30 Sigma-Aldrich (Nasdaq:,SIAL) today introduced ... http://www.sigma-aldrich.com/mdq1 . The,Methylated DNA Quantification Kit employs a familiar ELISA-like ...
... Olive stones can be turned into bioethanol, a renewable fuel ... an alternative to petrol or diesel. This gives the olive ... million tonnes of waste in olive stones it generates every ... products as fuels. Researchers from the Universities of Jan and ...
... under development at the National Institute of ... inexpensive optical microscope to quickly and cheaply ... Termed Through-focus Scanning Optical Microscope (TSOM) imaging, ... semiconductor process control and biotechnology. , Optical ...
Cached Biology Technology:Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 2Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 3Powered by olive stones? Turning waste stones into fuel 2Nanoscale dimensioning is fast, cheap with new NIST optical technique 2
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... new technique that can test for up to ... blood have scooped a prestigious national award which ... basophil-microarray based allergy assay is the brainchild of ... Pharmacy and Biosciences, in collaboration with colleagues in ...
... Writing in this week,s Journal of the ... urge physicians to test for mutations of the fragile ... after decades of research, it is clear that mutations ... neurodevelopmental delays and autism in children, infertility in women ...
... in the spotlight for its pivotal role in the Genomics ... in genomics to undergraduate classrooms across the country. ... of DNA), is an exciting area for students to get ... consists of over 40 faculty members from a variety of ...
Cached Biology News:Lab test for allergy scoops national 2Lab test for allergy scoops national 3M.I.N.D. Institute researchers call for fragile X testing throughout the lifespan 2M.I.N.D. Institute researchers call for fragile X testing throughout the lifespan 3Research-based undergraduate course expands beyond Washington University 2Research-based undergraduate course expands beyond Washington University 3Research-based undergraduate course expands beyond Washington University 4Research-based undergraduate course expands beyond Washington University 5
Please email us with project details and we will respond within 24 hours to your query!...
Request Info...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Biology Products: